AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

2021/05/26 by Joseph D. Feuerstein, Edith Y. Ho, Eugenia Shmidt +22 · 27 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Diverticular Disease and Complications #Autoimmune and Inflammatory Disorders

paper · pdf · doi:10.1053/j.gastro.2021.04.022

Citations

• Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
• AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease

Cited by

• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis
• Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice
• Biosimilar Uptake: The Importance of Healthcare Provider Education. [europepmc]
• Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study. [europepmc]
• Nutritional Therapies and Their Influence on the Intestinal Microbiome in Pediatric Inflammatory Bowel Disease. [europepmc]
• How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease. [europepmc]
• A review of the therapeutic management of Crohn's disease. [europepmc]
• Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. [europepmc]
• Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing? [europepmc]
• The Optimal Management of Fistulizing Crohn's Disease: Evidence beyond Randomized Clinical Trials. [europepmc]
• Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response. [europepmc]
• Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases. [europepmc]
• Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn's disease. [europepmc]
• A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application. [europepmc]
• Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. [europepmc]
• Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis. [europepmc]
• Is there an optimal sequence of biologic therapies for inflammatory bowel disease? [europepmc]
• Barriers to optimizing inflammatory bowel disease care in the United States. [europepmc]
• Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study. [europepmc]
• Unmet Challenges in Patients with Crohn's Disease. [europepmc]
• Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. [europepmc]
• Pharmacological Therapy in Inflammatory Bowel Diseases: A Narrative Review of the Past 90 Years. [europepmc]
• Vitamin D for the treatment of inflammatory bowel disease. [europepmc]
• AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. [europepmc]
• A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. [europepmc]
• Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey. [europepmc]
• British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. [europepmc]